Sangamo Therapeutics, Inc. (SGMO): Price and Financial Metrics

Sangamo Therapeutics, Inc. (SGMO)

Today's Latest Price: $9.63 USD

0.25 (2.67%)

Updated Jul 2 4:00pm

Add SGMO to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

SGMO Stock Summary

  • With a price/sales ratio of 11.75, Sangamo Therapeutics Inc has a higher such ratio than 89.02% of stocks in our set.
  • With a year-over-year growth in debt of 202.26%, Sangamo Therapeutics Inc's debt growth rate surpasses 92.8% of about US stocks.
  • As for revenue growth, note that SGMO's revenue has grown 34.48% over the past 12 months; that beats the revenue growth of 85.91% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Sangamo Therapeutics Inc are NTLA, DTIL, CDTX, JNCE, and SRRK.
  • Visit SGMO's SEC page to see the company's official filings. To visit the company's web site, go to
SGMO Daily Price Range
SGMO 52-Week Price Range

SGMO Stock Price Chart Technical Analysis Charts

SGMO Price/Volume Stats

Current price $9.63 52-week high $13.33
Prev. close $9.38 52-week low $4.81
Day low $9.30 Volume 1,382,094
Day high $9.69 Avg. volume 2,342,679
50-day MA $9.90 Dividend yield N/A
200-day MA $8.71 Market Cap 1.36B

Sangamo Therapeutics, Inc. (SGMO) Company Bio

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focused on the research, development, and commercialization of engineered DNA-binding proteins as novel therapeutic products for various monogenic and infectious diseases with unmet medical needs. The company was founded in 1995 and is based in Richmond, California.

SGMO Latest News Stream

Event/TimeNews Detail
Loading, please wait...

SGMO Latest Social Stream

Loading social stream, please wait...

View Full SGMO Social Stream

Latest SGMO News From Around the Web

Below are the latest news stories about Sangamo Therapeutics Inc that investors may wish to consider to help them evaluate SGMO as an investment opportunity.

Sangamo Announces R&D Organization Changes

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced changes to its research and development organization.

Yahoo | June 24, 2020

Hedge Funds Are Getting Crazy About Sangamo Therapeutics, Inc. (SGMO)

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

Yahoo | June 19, 2020

Pfizer's hemophilia gene therapy shows sustained effect in early-stage study

All five patients in an early-stage trial given the one-time treatment, giroctocogene fitelparvovec, did not have spontaneous bleeding episodes or require infusions of the blood-clotting protein they otherwise lack, the companies said. Pfizer and Sangamo's therapy is one of several treatments being developed for hemophilia A, as an alternative to the current practice that requires regular infusions to replace the missing protein, factor VIII. On Wednesday, a rival gene therapy by BioMarin Pharmaceutical Inc was found to reduce bleeding episodes by over 90% in patients treated four years ago.

Yahoo | June 18, 2020

Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy

Pfizer Inc. (NYSE:PFE) and Sangamo Therapeutics, Inc. (Nasdaq:SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525, or PF-07055480), an investigational gene therapy for patients with severe hemophilia A. All five patients with severe hemophilia A who received the 3e13 vg/kg dose showed sustained factor VIII (FVIII) activity levels, with a median of 64.2% via chromogenic assay (patient-level geometric means after week 9 post-infusion). No patients experienced bleeding events or required FVIII infusions. The factor VIII activity levels reflect measurements up to 61 weeks, the extent of follow-up for the longest-treated patient in the cohort. These data are being presented today as a late-breaking or...

Yahoo | June 18, 2020

Are Options Traders Betting on a Big Move in Sangamo (SGMO) Stock?

Investors need to pay close attention to Sangamo (SGMO) stock based on the movements in the options market lately.

Yahoo | June 16, 2020

Read More 'SGMO' Stories Here

SGMO Price Returns

1-mo -12.30%
3-mo 42.25%
6-mo 17.58%
1-year -15.53%
3-year 8.81%
5-year -1.63%
YTD 15.05%
2019 -27.09%
2018 -30.00%
2017 437.70%
2016 -66.59%
2015 -39.97%

Continue Researching SGMO

Want to see what other sources are saying about Sangamo Therapeutics Inc's financials and stock price? Try the links below:

Sangamo Therapeutics Inc (SGMO) Stock Price | Nasdaq
Sangamo Therapeutics Inc (SGMO) Stock Quote, History and News - Yahoo Finance
Sangamo Therapeutics Inc (SGMO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.1427 seconds.